|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,658,205
United States Patent 8,658,205, granted on February 25, 2014, to Bristol-Myers Squibb, covers methods related to the use of specific compounds for treating autoimmune diseases, including rheumatoid arthritis and psoriasis. The patent emphasizes novel chemical entities and their therapeutic applications, including formulations, dosing regimens, and specific claims about their utility.
Scope and Claims Analysis
What Are the Core Claims of Patent 8,658,205?
The patent contains 26 claims, primarily focused on:
-
Compound Composition Claims: Patent claims include chemical entities with defined structures targeting autoimmune conditions. These compounds are primarily derivatives or analogs of known immunomodulatory molecules.
-
Method of Use Claims: Claims extend to methods of treating autoimmune diseases by administering the compounds in specific dosages, formulations, and treatment regimens.
-
Formulation Claims: The patent details formulations suitable for administration, including dosages and combinations with other therapeutic agents.
-
Optional Combinations: Claims include the use of the compounds in combination with other drugs, such as methotrexate.
Key Claim Types and Their Limitations
| Claim Type |
Focus |
Scope |
Limitations |
| Compound Claims |
Chemical structure of compounds targeting IL-17 pathways |
Included specific structural formulas, chemical variations |
Limited to structures within the patent's specific scope |
| Method Claims |
Treatment methods for autoimmune diseases |
Administering compounds in certain dosages, for rheumatoid arthritis, psoriasis |
Specific to conditions, potentially broad but tied to compound's efficacy |
| Formulation Claims |
Dosage forms and delivery methods |
Oral, injectable formulations with specific compositions |
Encompasses standard pharmaceutical forms but limited to described compositions |
| Combination Claims |
Use with other drugs like methotrexate |
Co-administration with other known agents |
Narrow, limited to specified combinations |
Patent Specification and Disclosure
The specification discloses:
- Chemical synthesis routes for the compounds, including intermediates.
- Pharmacokinetic data demonstrating bioavailability.
- Efficacy data from preclinical or clinical models validating therapeutic benefits.
- Potential formulations including excipients and delivery methods.
- The focus on compounds acting as IL-17 pathway inhibitors aligns with targeting inflammatory autoimmune pathways.
Patent Landscape Context
Patent Families and Related Patents
- The patent is part of a broader patent family covering IL-17 pathway inhibitors and autoimmune disease therapeutics.
- Related patents include filings by Bristol-Myers Squibb covering similar compounds, formulations, and indications, notably U.S. Patent Nos. 8,663,942 and 8,844,176, which expand the chemical scope and claim broader formulations.
Competitor and Legal Landscape
- Competing patents from Merck, Novartis, and Johnson & Johnson also target IL-17 modulators or similar immunomodulatory compounds.
- Litigation and patent challenges have been minimal, though patent validity may be contested based on prior art disclosures in chemical and therapeutic areas.
Patent Expiry and Market Opportunities
- The patent expiry date, if maintained through pediatric extensions or other adjustments, is approximately February 2031.
- The patent provides exclusivity for Bristol-Myers Squibb’s IL-17 pathway inhibitors until patent expiration, shaping competitive landscape and licensing negotiations.
Trends in the Patent Landscape
- Increase in filings related to biologic and small molecule IL-17 inhibitors.
- Shift toward combination therapies with existing immunomodulators.
- Emphasis on formulations improving patient compliance, such as oral variants over injectable biologics.
Implications for R&D and Commercialization
- The patent’s claims protect Bristol-Myers Squibb’s specific chemical entities and their therapeutic uses, limiting competitors from manufacturing similar compounds for autoimmune indications.
- Broad method claims extend protection over various dosing regimes, but they are limited to the compounds described.
- Evolving landscape suggests potential for patent extensions or new filings covering improved formulations, delivery systems, or combination therapies.
Key Takeaways
- U.S. Patent 8,658,205 claims chemical compounds targeting autoimmune diseases, with method and formulation protections.
- The scope is centered on IL-17 pathway inhibitors, with specific structural features and use claims.
- The patent fits within a broader landscape of anti-IL-17 patents, with competitors actively developing similar therapeutics.
- Patent protection extends likely until 2031, with potential for tactical licensing or development around the claims.
FAQs
Q1. Does the patent cover all IL-17 inhibitors for autoimmune diseases?
No. It claims specific chemical structures and methods involving particular compounds. Other IL-17 inhibitors and broad classes remain unclaimed unless they fall within the defined structures or methods.
Q2. Can competitors develop similar compounds without infringing?
Yes. If they design molecules that differ from the specific structures claimed or utilize different methods, they can avoid infringement.
Q3. Are there ongoing patent challenges to this patent?
As of the knowledge cutoff in 2023, no publicly known challenges have compromised its validity, but legal challenges could still arise.
Q4. What is the patent’s geographical scope?
It primarily covers the United States. Bristol-Myers Squibb may have corresponding international patents to extend protection globally.
Q5. How does the patent impact biosimilar development?
It restricts biosimilar development of similar IL-17 inhibitors until expiration or invalidation, but chemical small molecules can be designed around the patent if structurally different.
Citations
[1] U.S. Patent No. 8,658,205. Bristol-Myers Squibb. "IL-17 pathway inhibitors and methods of treatment." 2014.
More… ↓
⤷ Start Trial
|
